HomeInsightsStock Comparison

Lupin Ltd vs Shilpa Medicare Ltd Stock Comparison

Lupin Ltd vs Shilpa Medicare Ltd Stock Comparison

Last Updated on: Jun 24, 2025

Key Highlights

  • The Latest Trading Price of Lupin Ltd is ₹ 1955 as of 24 Jun 11:04.
  • The P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 38.5 on March 2024 . This represents a CAGR of 0.26% over 4 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 12.8 on March 2020 to 125.7 on March 2024 . This represents a CAGR of 57.92% over 5 years.
  • The Market Cap of Lupin Ltd changed from ₹ 26713 crore on March 2020 to ₹ 73722 crore on March 2024 . This represents a CAGR of 22.51% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 1993 crore on March 2020 to ₹ 4004 crore on March 2024 . This represents a CAGR of 14.97% over 5 years.
  • The revenue of Lupin Ltd for the Mar '25 is ₹ 5724 crore as compare to the Dec '24 revenue of ₹ 5821 crore. This represent the decline of -1.67% The revenue of Shilpa Medicare Ltd for the Mar '25 is ₹ 340.68 crore as compare to the Dec '24 revenue of ₹ 320.79 crore. This represent the growth of 6.2%.
  • The ebitda of Lupin Ltd for the Mar '25 is ₹ 1378 crore as compare to the Dec '24 ebitda of ₹ 1409 crore. This represent the decline of -2.23% The ebitda of Shilpa Medicare Ltd for the Mar '25 is ₹ 58.56 crore as compare to the Dec '24 ebitda of ₹ 82.17 crore. This represent the decline of -28.73%.
  • The net profit of Lupin Ltd changed from ₹ 453.33 crore to ₹ 782.38 crore over 8 quarters. This represents a CAGR of 31.37% The net profit of Shilpa Medicare Ltd changed from ₹ 1.18 crore to ₹ 14.51 crore over 8 quarters. This represents a CAGR of 250.67% .
  • The Dividend Payout of Lupin Ltd changed from 37.36 % on March 2020 to 15.67 % on March 2024 . This represents a CAGR of -15.95% over 5 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.63 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Lupin Ltd

  • Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
  • The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
  • In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
  • In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

About Shilpa Medicare Ltd

  • Shilpa Medicare Limited (Formerly known as Shilpa Antibiotics Private Limited) was incorporated as a Private Limited Company on November 20, 1987.
  • The Company changed the status to Public Limited and the name of the Company was changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
  • The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
  • It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.

Lupin Ltd News Hub

News

Lupin inks licensing deal with Sino Universal pharma for Tiotropium DPI drug in China

As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in C...

Read more

16 Jun 2025 11:07

News

Lupin gets USFDA nod for Oxcarbazepine ER tablets

Oxcarbazepine ER tablets, 150 mg, 300 mg, and 600 mg are bioequivalent to Oxtellar XR ER t...

Read more

09 Jun 2025 08:23

News

Lupin allots 78,930 equity shares under ESOP

Lupin has allotted 78,930 equity shares under Stock Option plans of the Company. According...

Read more

27 May 2025 15:33

News

Lupin grants 7,337 stock options

Lupin has granted 7,337 stock options on 27 May 2025. Please note that upon vesting, one s...

Read more

27 May 2025 18:42

News

Lupin enters into license and supply agreement with SteinCares

Lupin has entered into a license and supply agreement with SteinCares, a leading specialty...

Read more

26 May 2025 10:27

News

Lupin to develop next-gen inhalers using Honeywell's Solstice' Air propellant

Lupin announced today its plan to use Honeywell's Solstice' Air (HFO-1234ze cGMP) propella...

Read more

20 May 2025 19:07

Shilpa Medicare Ltd News Hub

News

Board of Shilpa Medicare recommends final dividend

Shilpa Medicare announced that the Board of Directors of the Company at its meeting held o...

Read more

27 May 2025 11:37

News

Shilpa Medicare slides after Q4 PAT drop 41% YoY to Rs 15-cr

Profit before exceptional items and tax stood at Rs 43.35 crore in Q4 FY25, up 100.88% fro...

Read more

27 May 2025 16:01

News

Shilpa Medicare Ltd leads gainers in 'A' group

Netweb Technologies India Ltd, Linde India Ltd, Vaibhav Global Ltd and ITD Cementation Ind...

Read more

26 May 2025 12:00

News

Shilpa Medicare zooms as arm partners with Orion Corporation

Under this strategic agreement, Orion Corporation will serve as the exclusive partner for ...

Read more

23 May 2025 15:37

News

Shilpa Medicare to conduct board meeting

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 26 May 202...

Read more

19 May 2025 16:26

News

Shilpa Medicare gains after arm receives EIR from USFDA for unit-1 facility

In an exchange filing, the company stated that the USFDA has classified the inspection out...

Read more

15 May 2025 09:56

SWOT Analysis Of Lupin Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Shilpa Medicare Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Lupin Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Shilpa Medicare Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Lupin Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Lupin Ltd or Shilpa Medicare Ltd?

Market cap of Lupin Ltd is 88,055 Cr while Market cap of Shilpa Medicare Ltd is 8,617 Cr

What are the key factors driving the stock performance of Lupin Ltd and Shilpa Medicare Ltd?

The stock performance of Lupin Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lupin Ltd and Shilpa Medicare Ltd?

As of June 24, 2025, the Lupin Ltd stock price is INR ₹1928.1. On the other hand, Shilpa Medicare Ltd stock price is INR ₹881.25.

How do dividend payouts of Lupin Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Lupin Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions